TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: James Chih-Hsin Yang, Sanjay Popat, Silvia Novello, Harry J.M. Groen, Maurice Perol, Enriqueta Felip, Frank Griesinger, Karen L. Reckamp, Jong-Seok Lee, Egbert F. Smit, Collin M. Blakely, Wallace L. Akerley, Young-Chul Kim, Lyudmila Bazhenova, Raffaele Califano, Richard Delmar Hall, Panayiotis Georgiou, Jeffrey D. Isaacson, Tony Golsorkhi, Heather A. Wakelee
Institutions: National Taiwan University Hospital, Royal Marsden Hospital, University of Turin, University Medical Center Groningen, Centre Léon Bérard, Vall d'Hebron Institute of Oncology, Pius Hospital Oldenburg, City Of Hope National Medical Center, Seoul National University, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of California, San Francisco, University of Utah, Huntsman Cancer Institute, University of Utah Health Care, Chonnam National University Hwasun Hospital, University of California San Diego, The Christie Hospital, The Christie NHS Foundation Trust, University of Virginia Health System, Clovis Oncology (United States), Stanford Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891315685